GlassScriptPhysician profile
Brandon Kent
NPI 1083294656
$608.07
in general payments reported to CMS, 2019-2025
15 companies · $255 in 2025
The $255 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.10 · 2022: $194 · 2023: $89.90 · 2024: $56.46 · 2025: $255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $381 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $380.97 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz Pharmaceuticals, LLC | $167.56 | 2022-2025 | Xeomin |
| Abbvie INC. | $62.08 | 2023-2024 | |
| Averitas Pharma INC. | $58.32 | 2023-2025 | Qutenza |
| Boston Scientific Corporation | $48.51 | 2025 | Intracept |
| Biogen, INC. | $45.91 | 2025 | Leqembi |
| Ipsen Biopharmaceuticals, INC | $42.22 | 2022-2025 | Dysport |
| Ge Healthcare | $23.51 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $23.41 | 2024 | Iovera |
| Ucb, INC. | $23.27 | 2025 | Zilbrysq |
| Curonix LLC | $22.82 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Grt US Holding, INC. | $21.44 | 2022 | |
| Bioventus LLC | $19.37 | 2025 | Durolane |
| Azurity Pharmaceuticals, INC. | $18.73 | 2023 | Horizant |
| Genentech USA, INC. | $17.82 | 2025 | Ocrevus Zunovo |
| Stryker Corporation | $13.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Kent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.